Cargando…

CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS

BACKGROUND AND PURPOSE: High-grade gliomas are highly malignant, aggressive, high incidence rate, and mortality. The purpose of this study was to analyze retrospectively and identify prognostic factors of patients with high-grade gliomas diagnosed by biopsy or postoperative pathological examination....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shiyu, Jiang, Xin, Dong, Lihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354228/
http://dx.doi.org/10.1093/noajnl/vdac078.027
_version_ 1784763019729829888
author Liu, Shiyu
Jiang, Xin
Dong, Lihua
author_facet Liu, Shiyu
Jiang, Xin
Dong, Lihua
author_sort Liu, Shiyu
collection PubMed
description BACKGROUND AND PURPOSE: High-grade gliomas are highly malignant, aggressive, high incidence rate, and mortality. The purpose of this study was to analyze retrospectively and identify prognostic factors of patients with high-grade gliomas diagnosed by biopsy or postoperative pathological examination. METHODS: In this retrospective study, we analyzed the patient’s demographic data, tumor characteristics, treatment approaches, immunocytochemistry results, the overall survival (OS) time, and the progression-free survival (PFS) time in a series of 159 histologically proven high-grade gliomas recruited from January 2011 to December 2019. OS time and PFS time were analyzed by Kaplan-Meier survival analysis with log-rank test and found the independent factors by using Cox regression analysis. RESULTS: Survival analysis showed that an OS of 84.90%, 55.35% and 13.20% was observed at 1, 2 and 5 years, respectively. And a PFS of 56.6%, 25.26% and 3.14% was observed at 1, 2 and 5 years, respectively. The mean OS was 52.73 months and mOS was 35 months. Univariate analysis showed that postoperative pathological classification and grade and age were statistically significant for patient outcome (P < 0.01). 147 patients underwent concurrent chemoradiotherapy and 80 of them died; 12 patients did not undergo concurrent chemoradiotherapy and 10 died (P = 0.03); There were statistically significant differences in the prognostic impact of Ki-67 expression, MGMT, IDH1R132H and p53 mutations by immunohistochemistry (P = 0.001; P = 0.016; P = 0.003; and P = 0.021, respectively). Similarly, we concluded that different grades, age, pathological classification, Ki-67 and IDH1R132H expression by immunohistochemistry were statistically significantly associated with PFS (P < 0.01; P = 0.004; P = 0.003; P = 0.001; P = 0.028). CONCLUSIONS: Tumor grade and concurrent chemoradiotherapy after surgery were independent prognostic factors affecting patients’ survival, and grade was also an independent factor affecting PFS.
format Online
Article
Text
id pubmed-9354228
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93542282022-08-09 CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS Liu, Shiyu Jiang, Xin Dong, Lihua Neurooncol Adv Supplement Abstracts BACKGROUND AND PURPOSE: High-grade gliomas are highly malignant, aggressive, high incidence rate, and mortality. The purpose of this study was to analyze retrospectively and identify prognostic factors of patients with high-grade gliomas diagnosed by biopsy or postoperative pathological examination. METHODS: In this retrospective study, we analyzed the patient’s demographic data, tumor characteristics, treatment approaches, immunocytochemistry results, the overall survival (OS) time, and the progression-free survival (PFS) time in a series of 159 histologically proven high-grade gliomas recruited from January 2011 to December 2019. OS time and PFS time were analyzed by Kaplan-Meier survival analysis with log-rank test and found the independent factors by using Cox regression analysis. RESULTS: Survival analysis showed that an OS of 84.90%, 55.35% and 13.20% was observed at 1, 2 and 5 years, respectively. And a PFS of 56.6%, 25.26% and 3.14% was observed at 1, 2 and 5 years, respectively. The mean OS was 52.73 months and mOS was 35 months. Univariate analysis showed that postoperative pathological classification and grade and age were statistically significant for patient outcome (P < 0.01). 147 patients underwent concurrent chemoradiotherapy and 80 of them died; 12 patients did not undergo concurrent chemoradiotherapy and 10 died (P = 0.03); There were statistically significant differences in the prognostic impact of Ki-67 expression, MGMT, IDH1R132H and p53 mutations by immunohistochemistry (P = 0.001; P = 0.016; P = 0.003; and P = 0.021, respectively). Similarly, we concluded that different grades, age, pathological classification, Ki-67 and IDH1R132H expression by immunohistochemistry were statistically significantly associated with PFS (P < 0.01; P = 0.004; P = 0.003; P = 0.001; P = 0.028). CONCLUSIONS: Tumor grade and concurrent chemoradiotherapy after surgery were independent prognostic factors affecting patients’ survival, and grade was also an independent factor affecting PFS. Oxford University Press 2022-08-05 /pmc/articles/PMC9354228/ http://dx.doi.org/10.1093/noajnl/vdac078.027 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Liu, Shiyu
Jiang, Xin
Dong, Lihua
CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title_full CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title_fullStr CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title_full_unstemmed CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title_short CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
title_sort clrm-07 a multivariate retrospective analysis of 159 patients with high-grade gliomas: overall survival, progression-free survival, and prognostic factors
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354228/
http://dx.doi.org/10.1093/noajnl/vdac078.027
work_keys_str_mv AT liushiyu clrm07amultivariateretrospectiveanalysisof159patientswithhighgradegliomasoverallsurvivalprogressionfreesurvivalandprognosticfactors
AT jiangxin clrm07amultivariateretrospectiveanalysisof159patientswithhighgradegliomasoverallsurvivalprogressionfreesurvivalandprognosticfactors
AT donglihua clrm07amultivariateretrospectiveanalysisof159patientswithhighgradegliomasoverallsurvivalprogressionfreesurvivalandprognosticfactors